Successful treatment of bullous pemphigoid with omalizumab as corticosteroid‐sparing agent: report of two cases and review of literature

Balakirski, Galina; Alkhateeb, Abdulaziz; Merk, Hans F.; Leverkus, Martin; Megahed, Mosaad

doi:10.1111/jdv.13758

Cited by 59 publications

(36 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yayınlanmış verilere göre, küçük olgu serileri ve birkaç olgu raporunda OMZ yan etkisi olmayan ve başarılı bir ajan olarak bulunmuştur 18,19,21,26,27 . Buna ek olarak, önceki bildirilerde OMZ'nin steroid koruyucu etkilerini destekleyen sonuçlar vardır 27 . Oxford Kanıta Dayalı Tıp Merkezi'nin önerilerin kanıt derecelerine göre seviyelendirilmesinde BP için OMZ tartışmalı kanıt düzeyinde değerlendirilmiştir.…”

Section: Sonuçunclassified

Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid

Uysal¹,

Yalçın²,

Öktem³

2017

TURKDERM

View full text Add to dashboard Cite

Background and Design:In the era of biological therapies, omalizumab (OMZ), a monoclonal antibody which inhibits IgE, has been postulated to be effective in the treatment of bullous pemphigoid (BP). We report our clinical experience with the use of OMZ in the treatment of BP. Materials and Methods: Retrospective data analyses of eleven patients were performed. Results: Seven patients receiving OMZ treatment demonstrated clinical improvements. Three patients terminated treatment because of intermittent co-morbidities. None of the patients had any significant adverse events. Conclusion: OMZ may be a promising corticosteroid-sparing treatment option for moderate to severe BP patients. Future randomized controlled trials are indicated to evaluate the efficacy of OMZ in the treatment of BP. Büllöz pemfigoid tedavisinde omalizumab kullanımı üzerine klinik deneyimlerimiz

show abstract

Section: Sonuçunclassified

Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid

Uysal¹,

Yalçın²,

Öktem³

2017

TURKDERM

View full text Add to dashboard Cite

show abstract

“…High-affinity IgE receptor (FcεRI)-bound IgE on mast cells and eosinophils may be involved in the degranulation of such cells following their capture of shed extracellular fragments of COL17, in turn resulting in the development of urticarial erythema in BP 76 . Reports of BP cases successfully treated with anti-IgE monoclonal antibodies also support the potential of IgE as a therapeutic target in BP 77, 78 .…”

Section: Pemphigoidmentioning

confidence: 82%

Recent advances in the understanding and treatment of pemphigus and pemphigoid

Yamagami¹

2018

F1000Res

View full text Add to dashboard Cite

Pemphigus and pemphigoid are characterized as autoimmune blistering diseases in which immunoglobulin G autoantibodies cause blisters and erosions of the skin or mucosa or both. Recently, understanding of the pathophysiology of pemphigus and pemphigoid has been furthered by genetic analyses, characterization of autoantibodies and autoreactive B cells, and elucidation of cell–cell adhesion between keratinocytes. For the management of pemphigus and pemphigoid, the administration of systemic corticosteroids still represents the standard treatment strategy; however, evidence of the efficacy of therapies not involving corticosteroids, such as those employing anti-CD20 antibodies, is increasing. The goal should be to develop antigen-specific immune suppression-based treatments.

show abstract

“…To date, 15 cases of BP treated with omalizumab have been reported, with one of them at infant disease (Balakirski, Alkhateeb, Merk, Leverkus, & Megahed, 2016;Dufour et al, 2012;Gönül, Keseroglu, Ergin, Özcan, & Erdem, 2016;Menzinger, Kaya, Schmidt, Fontao, & Laffitte, 2018;Yalcin, Genc, Celik, & Gumuslu, 2014;Yu, Crew, Messingham, Fairley, & Woodley, 2014). Elevated IgE levels and/or eosinophilia are the leading facts to recommend this monoclonal antibody in BP (Yu et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report

Vico‐Alonso

Calleja‐Algarra

Aragón‐Miguel

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Bullous pemphigoid (BP) is an acquired autoimmune bullous disease characterized by autoantibodies against the hemidesmosomal proteins found in the basal keratinocytes of the basement membrane zone (BMZ): a 180 kDa protein (type XVII collagen) mainly and the 230 kDa antigen. There is such evidence that the antibodies against the BMZ components are not only of IgG type, but also this bullous disease may have IgE antibodies directed to the BMZ that contribute to the pathogenesis of the disorder. IgE is not only thought to contribute to the pathogenesis of BP, it has also been suggested that eosinophils play a role in the development of the first signs associated with BP. A humanized monoclonal antibody directed to IgE, omalizumab, is approved for the treatment of severe asthma and chronic spontaneous urticaria, and it may be useful in the treatment of BP in the first stages of the disease.

show abstract

Successful treatment of bullous pemphigoid with omalizumab as corticosteroid‐sparing agent: report of two cases and review of literature

Cited by 59 publications

References 30 publications

Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid

Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid

Recent advances in the understanding and treatment of pemphigus and pemphigoid

Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report

Contact Info

Product

Resources

About